GlobeImmune Files IPO to Raise $69M for Tarmogens
By Catherine Shaffer
Thursday, July 5, 2012
GlobeImmune Inc. filed for a $69 million initial public offering (IPO) to advance its cancer and infectious disease products developed using the Tarmogen platform.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.